🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. DCVax-L and T Cells

    NORTHWEST BIOTHERAPEUTICS INC

    Ovarian Cancer

    phase 2 mab terminated

    1 trial

  2. DESF

    Aquestive Therapeutics

    Allergic Reaction

    phase 2 small molecule completed

    1 trial

  3. DESTRESS-PC

    United Therapeutics Europe Ltd

    Posttraumatic Stress Disorder (PTSD)

    phase 2 other completed

    1 trial

  4. DEXAMETHASONE , PEGFILGRASTIM , Mosunetuzumab, DIPHENHYDRAMINE , RASBURICASE , Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, PREDNISONE , FLUDEOXYGLUCOSE (18F) , METHYLPREDNISOLONE, MabThera 500 mg concentrate for solution for infusion, PARACETAMOL, ALLOPURINOL

    Hoffmann-La Roche

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  5. DIMETHYL FUMARATE, DIMETHYL FUMARATE

    Pari Pharma GmbH

    Macular degeneration

    phase 2 small molecule active

    1 trial

  6. DISC-3405

    Disc Medicine

    Polycythemia Vera (PV)

    phase 2 small molecule active

    1 trial

  7. DM199

    DiaMedica Therapeutics

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  8. DM199

    DiaMedica Therapeutics

    Kidney Diseases

    phase 2 small molecule completed

    1 trial

  9. DMT210 Topical Gel

    Dermata Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  10. DMT210 Topical Gel 5%

    Dermata Therapeutics

    Acne Rosacea

    phase 2 small molecule completed

    1 trial

  11. DNA vaccine prime

    United Therapeutics Europe Ltd

    Malaria

    phase 2 mab completed

    1 trial

  12. DNL126

    Denali Therapeutics

    Mucopolysaccharidosis Type IIIA

    phase 2 small molecule active

    1 trial

  13. DNL593

    Denali Therapeutics

    Frontotemporal Dementia

    phase 2 small molecule active

    1 trial

  14. DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  15. DNTH103, Matching placebo to DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial

  16. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  17. DURVALUMAB, Ceralasertib

    Istituto Gentili S.r.l.

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  18. DURVALUMAB, PACLITAXEL ALBUMIN-BOUND, Ceralasertib

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  19. DYNE-101

    Dyne Therapeutics

    Myotonic Dystrophy Type 1 (DM1)

    phase 2 small molecule active

    1 trial

  20. DYNE-101, The placebo is commercially available 0.9% (w/v) saline solution intended for IV

    Dyne Therapeutics

    Myotonic Dystrophy Type 1

    phase 2 small molecule active

    1 trial

  21. DYNE-251

    Dyne Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  22. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  23. Dacogen 50 mg powder for concentrate for solution for infusion., Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

    Fondazione Telethon ETS

    Acute Myeloid Leukemia secondary to myeloproliferative neoplasms

    phase 2 small molecule active

    1 trial

  24. Darinaparsin

    Alaunos Therapeutics

    HEPATOCELLULAR CARCINOMA

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources